

A STUDY ON THE PUBLIC HEALTH AND SOCIOECONOMIC IMPACT

of substandard and falsified
medical products



World Health
Organization

A STUDY ON THE PUBLIC HEALTH AND SOCIOECONOMIC IMPACT

of substandard and falsified
medical products



**World Health
Organization**

A study on the public health and socioeconomic impact of substandard and falsified medical products
ISBN 978-92-4-151343-2

© World Health Organization 2017

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

Suggested citation. A study on the public health and socioeconomic impact of substandard and falsified medical products. Geneva: World Health Organization; 2017. Licence: CC BY-NC-SA 3.0 IGO.

Cataloguing-in-Publication (CIP) data. CIP data are available at <http://apps.who.int/iris>.

Sales, rights and licensing. To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

General disclaimers. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Printed in Switzerland

Layout by Jean-claude Fattier

Contents

ACKNOWLEDGEMENTS	V
ABBREVIATIONS AND ACRONYMS	VII
1 INTRODUCTION AND OVERVIEW	1
1.1 The need for evidence	1
1.2 Making the case for attention and investment	2
1.3 The study approach	2
2 PART ONE LITERATURE REVIEW	3
2.1 Methodology	3
2.1.1 Search strategy	3
2.1.2 Quality evaluation	4
2.1.3 Analysis of data	4
2.2 Results	4
2.2.1 Distribution by sampling strategy	5
2.2.2 Distribution by analytical technique	6
2.2.3 Distribution across countries by income level	6
2.2.4 Distribution across therapeutic categories	6
2.2.5 Estimated observed failure rate of substandard and falsified medical products	7
2.2.6 Estimated acquisition costs (spending)	8
2.3 Discussion	8
2.3.1 Impact of the survey methodology on results	8
2.3.2 Impact of varying testing methodologies	9
2.3.3 Impact of uneven distribution of field studies	9
2.3.4 Estimating prevalence of substandard and falsified medical products	9
2.3.5 Estimating acquisition costs (spending)	10
2.3.6 Impact of heterogeneous definitions	10
3 PART TWO IMPACT MODELS	11
3.1 Model 1: Childhood pneumonia	11
3.1.1 Introduction	11
3.1.2 Methodology	11
3.1.3 Results	12
3.1.4 Discussion	12
3.2 Model 2: Malaria in sub-Saharan Africa	13
3.2.1 Introduction	13
3.2.2 Methodology	13
3.2.3 Results	13
3.2.4 Discussion	14

4 PART THREE	KEY AREAS FOR CONSIDERATION	15
4.1	Public health impact	15
4.1.1	Mortality and morbidity	16
4.1.2	Disease prevalence	16
4.1.3	Antimicrobial resistance	16
4.1.4	Loss of confidence	17
4.2	Socioeconomic impact	17
4.2.1	Individual and household costs	17
4.2.2	Health systems costs	19
4.2.3	Socioeconomic costs	19
5	CONCLUSION	21
	REFERENCES	23
ANNEX 1:	WORLD BANK COUNTRY	
	CLASSIFICATION BY INCOME LEVEL	25
ANNEX 2:	LIST OF PAPERS INCLUDED	29
ANNEX 3:	MODEL 1 – CHILDHOOD PNEUMONIA,	
	UNIVERSITY OF EDINBURGH	35
	References	42
	Appendix: Childhood pneumonia	43
ANNEX 4:	MODEL 2 – MALARIA, LONDON SCHOOL	
	OF HYGIENE AND TROPICAL MEDICINE	45
	References	63
	Appendix: Antimalarial quality studies	65
ANNEX 5:	SOURCES OF DATA ON SUBSTANDARD AND	
	FALSIFIED MEDICINES	67



Acknowledgements

We wish to acknowledge the following for their contributions to this study.

Expert Working Group

Dr David Evans, Consultant and Chair, Switzerland; Aria Ilyad Ahmad, Consultant and Researcher, Canada; Dr Ricardo Cavazos, Comisión Federal para la Protección contra Riesgos Sanitarios, Mexico City, Mexico; Dr Lou Garrison, Professor Emeritus, University of Washington, Seattle, United States of America; Dr Catherine Goodman, Professor in Health Economics and Policy, London School of Hygiene and Tropical Medicine, England; Ms Erika Mattos da Veiga, Health Regulation Expert, Brazilian Health Regulatory Agency (ANVISA), Brasília, Brazil; Dr Anban Pillay, Deputy Director General, National Department of Health, Pretoria, South Africa; Dr Tomás Pippo, Director of Health Economics, Ministry of Health, Argentina; Dr Budiono Santoso, Vice Chairman, Gadjah Mada Medical Alumni Association, Yogyakarta, Indonesia; Dr Andreas Seiter, Senior Health Specialist, World Bank, Washington DC, United States of America.

Public health and socioeconomic impact models

Paediatric pneumonia model: Professor Harry Campbell, Co-Director, Centre for Global Health and WHO Collaborating Centre of Population Health Research and Training, University of Edinburgh, Scotland; Dr Evropi Theodoratou, Centre for Global Health Research, University of Edinburgh, Scotland.

Malaria (*Plasmodium falciparum*) model: Dr Catherine Goodman, Professor in Health Economics and Policy, Dr Shunmay Yeung, Associate Professor in Tropical Medicine; Mr David Bath, Research Fellow in Health Economics, London School of Hygiene and Tropical Medicine, United Kingdom.

Peer reviewers

Kiu Tay-Teo, Honorary Research Fellow, Melbourne School of Population and Global Health, Melbourne, Australia; Naomi van der Linden, PhD, University of Technology Sydney (UTS), Centre for Health Economics Research and Evaluation (CHERE), Sydney, Australia.

WHO Secretariat

Dr Suzanne Hill, Ms Emer Cooke, Dr Clive Ondari, Mr Michael Deats, Ms Diana Lee, Ms Pernette Bourdillon Esteve, Ms Lisa Greenough

We are also grateful to Member States for their valuable comments during the consultation process.

We wish to acknowledge the United States Food and Drug Administration who provided funding for the study.

Abbreviations and acronyms

ACT	artemisinin combination therapy
ALRI	acute lower respiratory infection
API	active pharmaceutical ingredient
CFR	case fatality rate
DALY	disability-adjusted life years
GSMS	Global Surveillance and Monitoring System
IOM	Institute of Medicine
LMICs	low- and middle-income countries
NMRA	national medicines regulatory authority
QALY	quality-adjusted life years
VR	vital registration

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_24712

